The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

Publications

Sugita Y, Ohwada C, Nagao Y, Kawajiri C, Shimizu R, Togasaki E, Yamazaki A, Muto T, Sakai S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Iseki T, Yokote K, Nakaseko C

Early-Onset Severe Diffuse Alveolar Hemorrhage after Bortezomib Administration Suggestive of Pulmonary Involvement of Myeloma Cells.

Journal of clinical and experimental hematopathology : JCEH. 2015;55(3):163-8

Wirk B

Bortezomib-related diffuse alveolar hemorrhage.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(36):e379-81

Pitini V, Arrigo C, Altavilla G, Naro C

Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?

Leukemia research. 2007;31(7):1027-8